Unicycive Therapeutics (UNCY) Stock Forecast & Price Target

Unicycive Therapeutics is well-positioned for success with a solid pipeline of promising products, a well-established partnership with the FDA, and a strong financial outlook. With a successful inspection expected in August 2026 and a potential PDUFA date in December of that year, we have a positive outlook and a 12-month price target of $15 per diluted share. Additionally, the company is currently preparing for commercial launch of OLC after the FDA's June 29 PDUFA and continues to engage with the agency on label and packaging discussions, indicating a strong likelihood of approval. With updates to the company's model reflecting strong quarterly results and a decrease in PT to $37 due to higher operating expenses and share count, we maintain a Buy rating and see potential for successful TDAPA designation and additional equity raise later this year to support the company's growth.

Unicycive Therapeutics is facing near-term launch delays for its phosphate binder product, leading to a revising down of its price target to $37, as it is actively preparing for launch and continuing to strengthen its balance sheet by utilizing its ATM program. It currently has a sufficient cash runway into 2027, but the conversion of warrants may dilute current shareholders, and the company may need to raise additional capital before becoming profitable in 2027. Any delays or challenges in commercial execution could further impact the company's valuation.